Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
March 24, 2023 07:00 ET
|
Purple Biotech Ltd.
Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEOCompany’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 ...
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
March 16, 2023 07:00 ET
|
Purple Biotech Ltd.
Reduction in neutrophil extracellular traps (NETs) markersPotential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- ...
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
February 14, 2023 07:01 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
February 08, 2023 07:12 ET
|
Purple Biotech Ltd.
Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
November 15, 2022 07:00 ET
|
Purple Biotech Ltd.
Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 2022 ...
Purple Biotech to Present at the Jefferies London Healthcare Conference
November 10, 2022 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,...
Purple Biotech Reports Third Quarter 2022 Financial Results
November 08, 2022 07:53 ET
|
Purple Biotech Ltd.
Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219 REHOVOT, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech Reports Second Quarter 2022 Financial Results
August 04, 2022 07:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients
May 18, 2022 08:18 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 18, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class,...
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
April 11, 2022 07:37 ET
|
Purple Biotech Ltd.
First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC REHOVOT, Israel, April 11, 2022 (GLOBE NEWSWIRE)...